Meanwhile, targeting FGF19 by shRNA or anti-FGF19 antibody neutralization or FGFR kinase inhibitors, LY2874455, BLU-554, and INCB06207, has been shown to inhibit the clonogenicity and tumorigenicity of FGF19 abnormal HCC (Hagel et al., 2015; Repana and Ross, 2015; Gao et al., 2017; Joshi et al., 2017; Kim et al., 2019a; Hatlen et al., 2019; Weiss et al., 2019). The gene discussed is FGF19; the disease is hepatocellular carcinoma.